Article
Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Sept 2026
Yumashev Alexei Valerievich, Shuxrat Boymuradov, Khayotbek Kasimov, Kodirov Umid, Elmurodova Aziza, Rufat Abdualimov, Urinova Nilufar, Abduraxmonova Iroda
Abstract excerpt
Cholangiocarcinoma (CCA), particularly the IDH-mutant subtype, presents major clinical challenges because it is frequently diagnosed at an advanced stage and carries a high risk of postoperative recurrence. Detecting minimal residual disease (MRD) is crucial, as it enables early identification of patients at high risk of relapse, guiding personalized adjuvant therapy to prevent recurrence and improve survival....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.